Valuation: Geron Corporation

Market Cap 790M 703M 651M 593M 1.12B 75.03B 1.14B 7.82B 3.07B 39.12B 2.97B 2.9B 125B P/E 2026 *
-27.9x
P/E 2027 * 17.2x
Enterprise Value 790M 703M 651M 593M 1.12B 75.03B 1.14B 7.82B 3.07B 39.12B 2.97B 2.9B 125B EV / Sales 2026 *
3.34x
EV / Sales 2027 * 2.31x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-4.88%
1 week-4.10%
Current month-4.88%
1 month-10.69%
3 months-17.61%
6 months-30.77%
Current year-11.36%
1 week 1.17
Extreme 1.17
1.24
1 month 1.17
Extreme 1.17
1.34
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-06
Director of Finance/CFO 59 2023-09-24
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 76 2010-05-20
Director/Board Member 72 2012-09-27
Director/Board Member 55 2019-03-25
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 Free

Director

6,351 0.0010%
6/30/26 Free

Director

6,103 0.0010%
5/20/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-4.88%-4.10%-8.59%-34.27% 790M
-6.60%-10.93%+45.08%+60.01% 68.98B
-4.09%+3.12%+3.71%+53.50% 53.15B
+0.03%+7.21%+12.52%+44.46% 50.83B
-1.53%+3.10%+31.40%+33.88% 44.61B
-5.97%-5.40%+259.08%+494.98% 40.57B
-1.34%+5.41%+16.74%+106.42% 42.53B
+6.53%+8.02%+18.98%+54.58% 30.95B
-0.90%-10.91%+34.11%-1.83% 25.44B
-2.76%-4.73%-15.94%-15.32% 22.66B
Average -2.15%+1.45%+39.71%+79.64% 38.05B
Weighted average by Cap. -2.43%+1.65%+46.39%+96.26%

Financials

2026 *2027 *
Net sales 236M 210M 195M 177M 334M 22.43B 340M 2.34B 918M 11.7B 887M 868M 37.33B 342M 304M 282M 257M 483M 32.47B 492M 3.38B 1.33B 16.93B 1.28B 1.26B 54.03B
Net income -27.18M -24.18M -22.39M -20.39M -38.43M -2.58B -39.14M -269M -106M -1.35B -102M -99.83M -4.29B 50.14M 44.62M 41.3M 37.62M 70.89M 4.76B 72.21M 496M 195M 2.48B 188M 184M 7.92B
Net Debt - -
Projected Income Statement - Annual - Geron Corporation
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
26-10-16 US$1.170 -4.88% 3,948,046
26-10-15 US$1.230 +3.36% 5,678,554
26-10-14 US$1.190 -0.83% 5,428,739
26-10-13 US$1.200 -1.64% 7,578,160
26-10-12 US$1.220 -0.41% 3,980,593
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Geron Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.170USD
Average target price
4.250USD
Spread / Average Target
+263.25%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Geron Corporation
  1. Stock Market
  2. Stocks
  3. GERN Stock